Pfenex and its partner Alvogen have submitted to the European Medicines Agency (EMA) a Marketing Authorization Application for PF708, which is a proposed biosimilar of teriparatide (Forteo), an osteoporosis drug.
Pfenex and its partner Alvogen have submitted to the European Medicines Agency (EMA) a Marketing Authorization Application (MAA) for PF708, which is a proposed biosimilar of teriparatide (Forteo), an osteoporosis drug.
“The acceptance of the PF708 MAA filing is an important milestone for Pfenex and Alvogen and demonstrates that through our collaborative partnership, we continue making progress towards potential approvals beyond the United States,” said Eef Schimmelpennink, chief executive officer of Pfenex, in a statement. “Subject to applicable regulatory approvals, for Europe, PF708 will be commercialized by Theramex, a leading global specialty pharmaceutical company dedicated to women’s health.”
Pfenex is also awaiting regulatory approval for the same product in the United states, where it submitted an application to the FDA for consideration in December 2018. Whereas in the European Union, subsequent-entry versions of teriparatide are regulated as biosimilars, in the United States, they are treated as follow-on products. As such, Pfenex has submitted a 505(b)(2) New Drug Application (NDA) rather than an abbreviated Biologics License Application for the product.
Although many products treated as drugs by the FDA (like insulins and hormones) will be regulated as biologics beginning on March 23, 2020, teriparatide is not on the FDA’s preliminary list of products that will make that transition. Thus, the product is expected to remain a follow-on in the US context.
Pfenex has indicated that it expects to be able to launch PF708 in the United States as early as the fourth quarter of 2019, where it could begin competing for the reference product’s estimated $1.6 billion in annual global product sales.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.